Fluorescence-guided surgical clinical trial with pHLIP® ICG imaging agent are initiated at the Memorial Sloan Kettering Cancer Center. The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI, and to see whether the use of the fluorescent imaging agent pHLIP ICG and NIRF imaging during surgery is a safe approach that may allow the surgeon to see the tumor and nearby tissues that contain cancer cells more clearly and remove them completely. The ClinicalTrials.gov identifier is NCT05130801, https://clinicaltrials.gov/ct2/show/NCT05130801
Cybrexa Therapeutics (pHLIP, Inc sublicensee) announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex™-exatecan, where alphalex™ consists of a pHLIP® peptide and linker), the company’s lead therapeutic candidate. The ClinicalTrials.gov identifier is NCT04902872, https://clinicaltrials.gov/ct2/show/NCT04902872